English deutsch Impressum
Sitemap Disclaimer
Company Product Investor Relations Newsroom Careers Contact
 

Overview
Collaborations
Partnering
People
 Management Team
 Supervisory Board
 Medical Advisory Board
History
Facility

Medical Advisory Board for RENCAREX®*

WILEX’s Medical Advisory Board for RENCAREX® is composed of international experts in the fields of biology and medicine, particularly oncologists and urologists.

Arie Belldegrun, MD, FACS (Chairman of the Advisory Board)
Roy and Carol Doumani Chair in Urologic Oncology;
Professor of Urology; and Chief, Division of Urologic Oncology;
Department of Urology at the David Geffen School of Medicine at UCLA, Los Angeles, CA.

Michael B. Atkins, MD, Deputy Director
Division of Hematology/Oncology, Beth Israel Deaconess Medical Center;
Leader of the Renal Cancer Program, Dana Farber-Harvard Cancer Center;
Professor of Medicine, Harvard Medical School, Boston, MA.

Michael L. Blute, MD
Chair of the Department of Urology, Mayo Clinic;
Anson L. Clark Professor of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota.

John Michael Fitzpatrick, MCh, FRCSI, FC Urol (SA), FRCSGlas, FRCS
Professor and Chairman, Department of Surgery, Mater Misericordiae Hospital, Dublin and University College;
Consultant Urologist, Mater Misericordiae Hospital, Dublin, Ireland.

Adrian L. Harris, MD, Ph.D.
Director of Cancer Research UK Medical Oncology Unit at the Churchill Hospital, University of Oxford;
Director of the Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine;
Consultant Medical Oncologist and Professorial Fellow of St Hugh's College Oxford.

Hakan Mellstedt, MD, Ph.D.
Chief Physician, Department of Oncology, Karolinska Hospital;
Professor of Oncologic Biotherapy at the Karolinska Institute;
Managing Director of Cancer Center Karolinska, Karolinska Institute, Stockholm, Sweden.

James E. Montie, MD
Valassis Professor of Urologic Oncology and Chairman, Department of Urology, University of Michigan, Ann Arbor, Michigan.

Jean-Jacques Patard, MD, Ph.D.
Professor of Urology, Department of Urology, University of Rennes, France.

Nicholas Vogelzang, MD
Director of the Nevada Cancer Institute, Las Vegas;
Clinical Professor of Medicine, University of Nevada School of Medicine, Las Vegas/Reno, NV.

* temporary name while under development